CLINICAL TRIALS PROFILE FOR VOXZOGO
✉ Email this page to a colleague
All Clinical Trials for VOXZOGO
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05845749 ↗ | Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI | Not yet recruiting | UCSF Benioff Children's Hospital Oakland | Phase 1/Phase 2 | 2023-07-01 | This is a Phase I/II, single arm, open label study of vosoritide therapy provided subcutaneously at 15 ug/kg/day for 48 weeks to 6 patients with MPS IVA or VI. Prior to enrollment in the interventional arm of study, subjects will be followed for a minimum of 24 weeks to gather information on safety profiles and determine annualized growth velocity. The primary study endpoint is the determination of safety and tolerability of daily vosoritide treatment in MPS. Exploratory endpoints include changes in linear and segmental growth as well as biomarkers of growth and bone metabolism. |
| NCT05849389 ↗ | Vosoritide for Short Stature in Turner Syndrome | Not yet recruiting | Roopa Kanakatti Shankar | Phase 2 | 2023-09-01 | Turner syndrome (TS) is characterized by a missing whole or part of the second sex chromosome in a phenotypic female, resulting in short stature due to haploinsufficiency of the SHOX gene. Growth hormone (GH) is an approved therapy for this condition, although not associated with GH deficiency, and benefits are modest. Vosoritide, a C-type natriuretic peptide (CNP) analog, targets chondrocytes within the growth plate leading to increased cell proliferation and hypertrophy. We hypothesize that patients with TS and short stature will respond to vosoritide treatment leading to increased growth velocity. This study will enroll pre-pubertal girls with TS who are either naïve to GH or have had a poor response to GH therapy. All subjects will be treated with vosoritide for 12 months and will be assessed for safety monitoring and improvement in height outcomes. Annualized growth velocity (AGV) on vosoritide will be compared to AGV in the 6-18 months prior to initiation of vosoritide based on historical data available in the medical record. Subjects with a positive response to therapy will be given the option to continue in the extension phase of the study during which they will continue to receive vosoritide until growth cessation. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for VOXZOGO
Condition Name
Clinical Trial Locations for VOXZOGO
Trials by Country
Clinical Trial Progress for VOXZOGO
Clinical Trial Phase
Clinical Trial Sponsors for VOXZOGO
Sponsor Name
